[Cost-effectiveness analysis of universal screening for thyroid disease in pregnant women in Spain]. 2015

Sergio Donnay Candil, and José Antonio Balsa Barro, and Julia Álvarez Hernández, and Carlos Crespo Palomo, and Ferrán Pérez-Alcántara, and Carlos Polanco Sánchez
Unidad de Endocrinología y Nutrición, Hospital Universitario Fundación Alcorcón, Madrid, España. Electronic address: SDonnay@fhalcorcon.es.

OBJECTIVE To assess the cost-effectiveness of universal screening for thyroid disease in pregnant women in Spain as compared to high risk screening and no screening. METHODS A decision-analytic model comparing the incremental cost per quality-adjusted life year (QALY) of universal screening versus high risk screening and versus no screening. was used for the pregnancy and postpartum period. Probabilities from randomized controlled trials were considered for adverse obstetrical outcomes. A Markov model was used to assess the lifetime period after the first postpartum year and account for development of overt hypothyroidism. The main assumptions in the model and use of resources were assessed by local clinical experts. The analysis considered direct healthcare costs only. RESULTS Universal screening gained .011 QALYs over high risk screening and .014 QALYS over no screening. Total direct costs per patient were €5,786 for universal screening, €5,791 for high risk screening, and €5,781 for no screening. Universal screening was dominant compared to risk-based screening and a very cost-effective alternative as compared to no screening. Use of universal screening instead of high risk screening would result in €2,653,854 annual savings for the Spanish National Health System. CONCLUSIONS Universal screening for thyroid disease in pregnant women in the first trimester is dominant in Spain as compared to risk-based screening, and is cost-effective as compared to no screening (incremental cost-effectiveness ratio of €374 per QALY). Moreover, it allows diagnosing and treating cases of clinical and subclinical hypothyroidism that may not be detected when only high-risk women are screened.

UI MeSH Term Description Entries
D007037 Hypothyroidism A syndrome that results from abnormally low secretion of THYROID HORMONES from the THYROID GLAND, leading to a decrease in BASAL METABOLIC RATE. In its most severe form, there is accumulation of MUCOPOLYSACCHARIDES in the SKIN and EDEMA, known as MYXEDEMA. It may be primary or secondary due to other pituitary disease, or hypothalamic dysfunction. Central Hypothyroidism,Primary Hypothyroidism,Secondary Hypothyroidism,TSH Deficiency,Thyroid-Stimulating Hormone Deficiency,Central Hypothyroidisms,Deficiency, TSH,Deficiency, Thyroid-Stimulating Hormone,Hormone Deficiency, Thyroid-Stimulating,Hypothyroidism, Central,Hypothyroidism, Primary,Hypothyroidism, Secondary,Hypothyroidisms,Primary Hypothyroidisms,Secondary Hypothyroidisms,TSH Deficiencies,Thyroid Stimulating Hormone Deficiency,Thyroid-Stimulating Hormone Deficiencies
D007752 Obstetric Labor, Premature Onset of OBSTETRIC LABOR before term (TERM BIRTH) but usually after the FETUS has become viable. In humans, it occurs sometime during the 29th through 38th week of PREGNANCY. TOCOLYSIS inhibits premature labor and can prevent the BIRTH of premature infants (INFANT, PREMATURE). Preterm Labor,Labor, Premature,Premature Labor,Premature Obstetric Labor,Labor, Premature Obstetric,Labor, Preterm
D008403 Mass Screening Organized periodic procedures performed on large groups of people for the purpose of detecting disease. Screening,Mass Screenings,Screening, Mass,Screenings,Screenings, Mass
D009313 National Health Programs Components of a national health care system which administer specific services, e.g., national health insurance. National Health Insurance, Non-U.S.,Health Services, National,National Health Insurance,National Health Insurance, Non U.S.,National Health Services,Services, National Health,Health Insurance, National,Health Program, National,Health Programs, National,Health Service, National,Insurance, National Health,National Health Program,National Health Service,Program, National Health,Programs, National Health,Service, National Health
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D011248 Pregnancy Complications Conditions or pathological processes associated with pregnancy. They can occur during or after pregnancy, and range from minor discomforts to serious diseases that require medical interventions. They include diseases in pregnant females, and pregnancies in females with diseases. Adverse Birth Outcomes,Complications, Pregnancy,Adverse Birth Outcome,Birth Outcome, Adverse,Complication, Pregnancy,Outcome, Adverse Birth,Pregnancy Complication
D011256 Pregnancy Outcome Results of conception and ensuing pregnancy, including LIVE BIRTH; STILLBIRTH; or SPONTANEOUS ABORTION. The outcome may follow natural or artificial insemination or any of the various ASSISTED REPRODUCTIVE TECHNIQUES, such as EMBRYO TRANSFER or FERTILIZATION IN VITRO. Outcome, Pregnancy,Outcomes, Pregnancy,Pregnancy Outcomes
D011261 Pregnancy Trimester, First The beginning third of a human PREGNANCY, from the first day of the last normal menstrual period (MENSTRUATION) through the completion of 14 weeks (98 days) of gestation. Early Placental Phase,Pregnancy, First Trimester,Trimester, First,Early Placental Phases,First Pregnancy Trimester,First Pregnancy Trimesters,First Trimester,First Trimester Pregnancies,First Trimester Pregnancy,First Trimesters,Phase, Early Placental,Phases, Early Placental,Placental Phase, Early,Placental Phases, Early,Pregnancies, First Trimester,Pregnancy Trimesters, First,Trimesters, First
D003198 Computer Simulation Computer-based representation of physical systems and phenomena such as chemical processes. Computational Modeling,Computational Modelling,Computer Models,In silico Modeling,In silico Models,In silico Simulation,Models, Computer,Computerized Models,Computer Model,Computer Simulations,Computerized Model,In silico Model,Model, Computer,Model, Computerized,Model, In silico,Modeling, Computational,Modeling, In silico,Modelling, Computational,Simulation, Computer,Simulation, In silico,Simulations, Computer
D003362 Cost-Benefit Analysis A method of comparing the cost of a program with its expected benefits in dollars (or other currency). The benefit-to-cost ratio is a measure of total return expected per unit of money spent. This analysis generally excludes consideration of factors that are not measured ultimately in economic terms. In contrast a cost effectiveness in general compares cost with qualitative outcomes. Cost and Benefit,Cost-Benefit Data,Benefits and Costs,Cost Benefit,Cost Benefit Analysis,Cost-Utility Analysis,Costs and Benefits,Economic Evaluation,Marginal Analysis,Analyses, Cost Benefit,Analysis, Cost Benefit,Analysis, Cost-Benefit,Analysis, Cost-Utility,Analysis, Marginal,Benefit and Cost,Cost Benefit Analyses,Cost Benefit Data,Cost Utility Analysis,Cost-Benefit Analyses,Cost-Utility Analyses,Data, Cost-Benefit,Economic Evaluations,Evaluation, Economic,Marginal Analyses

Related Publications

Sergio Donnay Candil, and José Antonio Balsa Barro, and Julia Álvarez Hernández, and Carlos Crespo Palomo, and Ferrán Pérez-Alcántara, and Carlos Polanco Sánchez
June 2008, European journal of endocrinology,
Sergio Donnay Candil, and José Antonio Balsa Barro, and Julia Álvarez Hernández, and Carlos Crespo Palomo, and Ferrán Pérez-Alcántara, and Carlos Polanco Sánchez
May 2012, The Journal of clinical endocrinology and metabolism,
Sergio Donnay Candil, and José Antonio Balsa Barro, and Julia Álvarez Hernández, and Carlos Crespo Palomo, and Ferrán Pérez-Alcántara, and Carlos Polanco Sánchez
June 1999, BMJ (Clinical research ed.),
Sergio Donnay Candil, and José Antonio Balsa Barro, and Julia Álvarez Hernández, and Carlos Crespo Palomo, and Ferrán Pérez-Alcántara, and Carlos Polanco Sánchez
March 2021, Journal of clinical gastroenterology,
Sergio Donnay Candil, and José Antonio Balsa Barro, and Julia Álvarez Hernández, and Carlos Crespo Palomo, and Ferrán Pérez-Alcántara, and Carlos Polanco Sánchez
November 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research,
Sergio Donnay Candil, and José Antonio Balsa Barro, and Julia Álvarez Hernández, and Carlos Crespo Palomo, and Ferrán Pérez-Alcántara, and Carlos Polanco Sánchez
January 2016, Pathogens and global health,
Sergio Donnay Candil, and José Antonio Balsa Barro, and Julia Álvarez Hernández, and Carlos Crespo Palomo, and Ferrán Pérez-Alcántara, and Carlos Polanco Sánchez
February 2005, Journal of acquired immune deficiency syndromes (1999),
Sergio Donnay Candil, and José Antonio Balsa Barro, and Julia Álvarez Hernández, and Carlos Crespo Palomo, and Ferrán Pérez-Alcántara, and Carlos Polanco Sánchez
November 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
Sergio Donnay Candil, and José Antonio Balsa Barro, and Julia Álvarez Hernández, and Carlos Crespo Palomo, and Ferrán Pérez-Alcántara, and Carlos Polanco Sánchez
January 2011, Annals of agricultural and environmental medicine : AAEM,
Sergio Donnay Candil, and José Antonio Balsa Barro, and Julia Álvarez Hernández, and Carlos Crespo Palomo, and Ferrán Pérez-Alcántara, and Carlos Polanco Sánchez
April 2000, Pediatrics,
Copied contents to your clipboard!